Pharma BD Deal Intelligence

Endo Pharmaceuticals Holdings Inc. / Algos Pharmaceutical Corporation

2000 · Acquisition/Merger · $250M · Complete

Announcement Sentiment

Skeptical

Endo completed a $250M stock-swap acquisition of Algos Pharmaceutical (originally announced Nov 1999, repriced and closed Jul 17, 2000). Brought MorphiDex pain combination. The deal also took Endo public (Nasdaq: ENDP). MorphiDex later failed Phase 3 in 2002.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Impaired/Written Down

Pipeline outcome

Assets Terminated

Assessment window: 5yr post-close.

Key facts

Announced Jul 17, 2000
Closed Jul 17, 2000
Deal value $250M
Deal type Acquisition/Merger
Therapeutic area Moderate-to-severe cancer pain
Indications Moderate-to-severe cancer pain
Key assets MorphiDex (morphine + dextromethorphan)
Mechanism Mu-opioid agonist + NMDA receptor antagonist combination

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals